Buy Active Pharmaceutical Ingredients from Top Suppliers, Manufacturers

chemical-categories

Piroxicam

Piroxicam is a non-steroidal anti-inflammatory drug of the oxicam class used to relieve the symptoms of rheumatoid and osteoarthritis, primary dysmenorrhoea, postoperative pain,and act as an analgesic.It is also used in veterinary medicine to treat certain neoplasias expressing cyclooxygenase (COX) receptors, such as bladder, colon, and prostate cancers.

Properties Suppliers
Pregabalin

* CAS No.: 148553-50-8 * IUPAC Name: (S)-3- aminomethyl-5-methylhexanoic acid * Molecular weight: 159.23 g/mol * Chemical Formula: C8H17NO2 * Assay/Purity: NLT 98.0% * Description: A white to off-white powder * Category: Anti-epileptic * Indications: Used for neuropathic pain and as an adjunct therapy for partial seizures. It has also been found effective for generalized anxiety disorder.

Properties Suppliers
Pregabalin Purified >99%

We can supply Pregabalin  Ph.Eur / IH / IP grades 

DMF (CTD) format is also avalibale.

Properties Suppliers
R428 LAB GRADE 98%

BGB-324,CAS 1037624-75-1  also known as R428, is a selective small molecule inhibitor of Axl kinase, which showed activity to blocks tumor spread and prolongs survival in models of metastatic breast cancer. The receptor tyrosine kinase Axl may play an important role in cancer progression, invasion, metastasis, drug resistance, and patient mortality. R428 inhibits Axl with low nanomolar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production.

Properties Suppliers
RAF265 Technical 90%

RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM.

in vitro: RAF265 inhibits C-Raf, wild type B-Raf and mutant (V600E) B-Raf. RAF265 effectively block phosphorylation of Raf's downstream substrates MEK and ERK in cells and also kill melanoma and colorectal cancer cell lines harboring B-Raf mutations independent of PTEN mutation status. Raf kinase inhibition by RAF265 in mutant B-Raf melanoma cell lines causes cell cycle arrest and induces apoptosis, mimicking the effect of Raf RNAi in these cells. RAF265 also potently inhibits the phosphorylation of VEGFR2 and proliferation of VEGF-stimulated hMVEC [1]. In HT29 and MDAMB231 cells, RAF265 shows inhibitory activity with IC20 of 1 to 3 μM and IC50 of 5 to 10 μM, respectively. While RAF265 leads to a significant decrease in clonogenic survival in all tested cell lines, which means that RAF265 induces a dominant effect on clonogenic survival. Addition of RAF265 to RAD001 in HCT116 cells could lead to moderately decreased AKT, S6 protein, and 4EBP1 phosphorylation [2]. Raf265 markedly reduces the protein level of Bcl-2 and great inhibitory in CM- and NCI-H727 cells, while having no effect on the TRAIL susceptibility of BON1 and GOT1 cells [3].

in vivo: AF265 shows 71% to 72% TVI% (tumor volume inhibition percentage) in HCT116 xenografts at 12 mg/kg. While the combination of RAF265 and RAD001 shows enhanced antitumor activity with increased T10 (time to achieve a relative tumor volume of 10 times the initial tumor volume) and tumor growth delay. The combination of RAD001 and RAF265 also significantly enhances the activation of caspase-3 in HCT116 and MDAMB231 but not in A549 xenografts [2]. RAF265 inhibits FDG (2-deoxy-2-[18F]fluoro-d-glucose) accumulation and decreases the tumor volumes in A375M xenografts by orally dosed of 100 mg/kg [4].

Properties Suppliers
RSM932A LAB GRADE

RSM-932A CAS 850807-63-5  is a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells. RSM-932A appears to have an altogether novel mechanism of inhibition and is synergistic with respect to both choline and ATP. RSM-932A have in vitro inhibitory activity in the low nanomolar range. RSM-932A significantly reduced parasitemia and induced the accumulation of trophozoites and schizonts, blocking intraerythrocytic development and interfering with parasite egress or invasion, suggesting a delay of the parasite maturation stage. RSM-932A has been chosen for further clinical development due to its potent antiproliferative activity in vitro against a large variety of tumor-derived cell lines, a potent in vivo anticancer activity, and lack of toxicity at the effective doses

Properties Suppliers
Rebamipide

Rebamipide an amino acid derivative of 2(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis and also used as a long-term treatment for Behcet's disease. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2.

Properties Suppliers
Regorafenib 99%

Shanghai Ansion Pharma Technology Co.,Ltd
www.ansionpharma.com
ann.xu@ansionpharma.com

Properties Suppliers
Rocuronium Bromide

Those products patented are for laboratory analytical/research purpose only, not offered for sale in countries where the sales of sunch products constitutes patent infringement, otherwise the following liability is at buyer’s rick.

Properties Suppliers